Name: BICARA THERAPEUTICS INC (BCAX) Stock
Brand: BICARA THERAPEUTICS INC
Rating: 5 (3 reviews)

BCAX Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

21 hours ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

a month ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

a month ago - By: Benzinga - Mentions: XBI ALDX APLT NGNE

4 Biotech Stocks Seeing Explosive Momentum Gains

3 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics to Participate in Upcoming Investor Conferences

3 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics to Participate in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?

3 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Relay Therapeutics, Inc. - Mentions: RLAY

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

5 months ago - By: Benzinga - Mentions: BOLT CLRB MESO CBUS ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

5 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

5 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

5 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

5 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

6 months ago - By: Yahoo Finance - Mentions: NRXP USB JAKK IVR ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

6 months ago - By: Yahoo Finance - Mentions: MS CPNG TGT CRM ...

Morgan Stanley Names Coupang (CPNG) Its New Top Pick, Lifts PT

6 months ago - By: Yahoo Finance - Mentions: MS GMED MDT SE ...

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

6 months ago - By: Yahoo Finance - Mentions: MS NIO TSLA RZB ...

Morgan Stanley Maintains Buy rating on NIO Inc (NIO)

6 months ago - By: Yahoo Finance

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

6 months ago - By: Investor's Business Daily - Mentions: MRUS MRK

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

6 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

6 months ago - By: Bicara Therapeutics Inc.

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

6 months ago - By: Bicara Therapeutics Inc.

BICARA THERAPEUTICS INC (BCAX) Stock News

BCAX Latest News, Press Relases and Analysis

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC

4 Biotech Stocks Seeing Explosive Momentum Gains

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

12 Health Care Stocks Moving In Wednesday's After-Market Session

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network

Morgan Stanley Names Coupang (CPNG) Its New Top Pick, Lifts PT

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

Morgan Stanley Maintains Buy rating on NIO Inc (NIO)

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update